CRISPR Therapeutics Reports Q4 & FY25 Results, Highlights Strong CASGEVY Uptake & Pipeline Progress

summarizeSummary

CRISPR Therapeutics announced its Q4 and full-year 2025 financial results, reporting $116 million in annual CASGEVY revenue and significant progress across its broad gene-editing pipeline, including new clinical trial initiations.

check_boxKey Events

• Strong CASGEVY Revenue Growth

  Reported $54 million in Q4 2025 and $116 million in full-year 2025 revenue for CASGEVY, with patient initiations nearly tripling compared to the prior year.

• Robust Pipeline Progression

  Advanced multiple gene-editing programs, including CTX460, CTX340, and CTX213, with several new clinical trial initiations anticipated in H1/mid-2026.

• Widened Net Loss

  Reported a net loss of $130.6 million for Q4 2025 and $581.6 million for the full year, primarily due to increased collaboration expenses, while maintaining a strong cash position of $1.97 billion.

• FDA Priority Voucher

  Received an FDA Commissioner's National Priority Voucher for pediatric CASGEVY submissions, expected to commence in the first half of 2026.

auto_awesomeAnalysis

The report provides a comprehensive update on CRISPR Therapeutics' financial performance and extensive pipeline. While the company reported a widened net loss for Q4 and FY2025, primarily due to increased collaboration expenses, its cash position remains robust. A key highlight is the commercial ramp-up of CASGEVY, which generated $116 million in full-year revenue, with patient initiations nearly tripling in 2025. The company also detailed advancements across its in vivo liver editing, siRNA, autoimmune, immuno-oncology, and regenerative medicine programs, with several new clinical trial initiations anticipated in the first half of 2026. The FDA's award of a National Priority Voucher for pediatric CASGEVY submissions further underscores regulatory progress.